This FAQ provides key information on vaccines and therapeutics for Bundibugyo virus disease (BVD), including current evidence, ongoing research, WHO recommendations, and key messages for national authorities and communities.
This document will be updated as new information becomes available.
Année de publication
2026
ebola-BDBV
Cette ressource apparaît sur le Thème suivant:
Cette ressource est incluse dans le tableau suivant:
| Titre | Auteur | Année | Type | Langue |
|---|
| WHO Technical Advisory Group on candidate vaccine prioritization (TAG-CVP) for BVD candidate vaccine prioritization (TAG-CVP) meeting report, 31 July 2026 | World Health Organization (WHO) | 2026 | Report | Anglais |
| Frequently asked questions (FAQs) on Bundibugyo Virus Disease vaccines and therapeutics | World Health Organization (WHO), WHO Regional Office for Africa (AFRO) | 2026 | Datasheet | Anglais, Français |
| GNN webinar: Updates on existing and pipeline Ebola vaccines | Helen Rees, Reena Doshi, Alejandro Costa, Melanie Marti, Pierre Gsell | 2026 | Webinar | Anglais |
| WHO emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks: interim guidance, 31 August 2026 | World Health Organization (WHO) | 2026 | Guidance | Anglais, Français |
| WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks, 28 May 2026 | World Health Organization (WHO) | 2026 | Guidance | Anglais |
| WHO target product profile for Bundibugyo virus disease vaccines | World Health Organization (WHO) | 2026 | Report | Anglais |
| WHO Technical Advisory Group on Candidate Vaccine Prioritization Meeting report, 19 and 25 May 2026 | World Health Organization (WHO) | 2026 | Report | Anglais |
Ajouté par: Reena Doshi
Ajouté le: 2026-06-09 09:45:57
Consultations: 554
